Tag: PCSK9 inhibitor

The European Commission authorise use of evolocumab to reduce risk of...

The European Commission (EC) has authorised a new indication in the evolocumab (Repatha, Amgen) label for adults with established atherosclerotic cardiovascular disease—myocardial infarction, stroke...

ADVERTORIAL: Taking control of LDL-C when statin therapy is not enough

This content is for distribution within the UK only. This content is for distribution within the UK only. Currently, statins are the most common lipid-lowering therapy...

ACC 2017: PCSK9 inhibitor evolocumab significantly reduces the risk of cardiovascular...

Data for a new drug that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) show that it is associated with a near 60% reduction in...

AHA 2016: The Medicines Company and Alnylam Pharmaceuticals present positive results...

The Medicines Company and Alnylam Pharmaceuticals have announced positive results from the analysis of day 90 data for 497 patients, as well as analysis...

Pfizer discontinues the global development of its investigational PCSK9 inhibitor

Pfizer is to discontinue the global clinical development program for bococizumab—its investigational PCSK9 inhibitor. According to a press release, the totality of clinical information...